Please login to the form below

Not currently logged in
Email:
Password:

patent challenge

This page shows the latest patent challenge news and features for those working in and with pharma, biotech and healthcare.

FDA starts review of Biogen’s Tecfidera follow-up for MS

FDA starts review of Biogen’s Tecfidera follow-up for MS

It’s under threat from a patent challenge from generic drugmaker Mylan, however, which if successful could carve years off Biogen’s marketing exclusivity for the drug in the US from ... Meanwhile, a patent opposition lawsuit is also ongoing in Europe.

Latest news

  • Morphosys’ Darzalex patent challenge hits a hurdle Morphosys’ Darzalex patent challenge hits a hurdle

    Genmab and J&J's myeloma drug is a blockbuster. A US court has sided against Morphosys in its patent dispute with Genmab and Johnson &Johnson over myeloma blockbuster Darzalex, blocking ... Morphosys started its patent infringement claim in 2016, shortly

  • First blood to Roche in Hemlibra patent fight with Shire First blood to Roche in Hemlibra patent fight with Shire

    The new haemophilia drug does not infringe Baxalta’s patent, rules Tokyo court. ... Roche’s defence of its haemophilia drug Hemlibra against a patent infringement challenge by Shire has been buoyed by a Japanese ruling.

  • Shire claims FDA approval for slow-cooked ADHD drug Shire claims FDA approval for slow-cooked ADHD drug

    Either way the new drug is a boost to Shire's ADHD franchise now that Adderall XR and Intuniv (guanfacine) have lost patent protection in most major markets, and along with ... Vyvanse remains under patent challenge from would-be generic rivals, but so

  • Merck plans expanded filing for Emend this year Merck plans expanded filing for Emend this year

    The US patent for the oral formulation expires this year, but the injectable remains protected until 2019, according to Merck. ... In the meantime Merck is also facing a challenge on its injectable patent from Apotex, which filed a petition with the US

  • China turns down one of two Sovaldi patents China turns down one of two Sovaldi patents

    The challenge to the Chinese patent was filed by the Initiative for Medicines, Access &Knowledge (I-MAK), an advocacy group that is trying to overturn Gilead's intellectual property for Sovaldi ... that are currently reviewing patent applications for the

More from news
Approximately 1 fully matching, plus 44 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Indians scalp cowboys in patent war

    claims?  . You can expect lawyers working for generics manufacturers to vigorously challenge the Allergan strategy. ... At the same time, imaginative patent lawyers will be racking their brains to exploit new opportunities.  .

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics